Anti-interleukin-6 receptor antibody treatment ameliorates postoperative adhesion formation

被引:39
|
作者
Uyama, Naoki [1 ]
Tsutsui, Hiroko [1 ]
Wu, Songtao [1 ]
Yasuda, Koubun [2 ]
Hatano, Etsuro [1 ]
Qin, Xian-Yang [3 ]
Kojima, Soichi [3 ]
Fujimoto, Jiro [1 ]
机构
[1] Hyogo Coll Med, Dept Surg, Nishinomiya, Hyogo, Japan
[2] Hyogo Coll Med, Dept Immunol, Nishinomiya, Hyogo, Japan
[3] RIKEN Ctr Integrat Med Sci, Liver Canc Prevent Res Unit, Wako, Saitama, Japan
关键词
TGF-BETA; NEUTROPHIL ELASTASE; INTERFERON-GAMMA; MASTER REGULATOR; LIVER FIBROSIS; TISSUE-REPAIR; INTERLEUKIN-6; MYOFIBROBLAST; MECHANISMS; MACROPHAGES;
D O I
10.1038/s41598-019-54175-1
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Postoperative adhesion formation often ruins the quality of life or is an obstacle to illnesses with curative operation such as cancer. Previously we demonstrated that interferon-gamma-promoted fibrin deposition drove postoperative adhesion formation. However, its underlying cellular and molecular mechanisms remain poorly understood. We found that myofibroblasts of the adhesion predominantly expressed signature molecules of mesothelial cells that line the serosa. Microarray analysis revealed IL-6 as a key underlying player, supported by elevated IL-6 levels in the peritoneal fluid of postlaparotomy human subjects. Injured serosa of cecum-cauterized mice also exhibited induction of Il6, which was followed by Tnf, concomitant with rapid accumulation of neutrophils, substantial population of which expressed TGF-beta 1, a master regulator of fibrosis. Besides, neutrophil-ablated mice showed reduction in induction of the adhesion, suggesting that TGF-beta 1(+)neutrophils triggered the adhesion. Human neutrophils expressed TGFB1 in response to TNF-alpha and TNF in response to IL-6. Moreover, anti-IL-6 receptor monoclonal antibody abrogated neutrophil recruitment and adhesion formation. Thus, IL-6 signaling represents a potential target for the prevention of postoperative adhesions.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Anti-interleukin-6 receptor antibody treatment ameliorates postoperative adhesion formation
    Naoki Uyama
    Hiroko Tsutsui
    Songtao Wu
    Koubun Yasuda
    Etsuro Hatano
    Xian-Yang Qin
    Soichi Kojima
    Jiro Fujimoto
    [J]. Scientific Reports, 9
  • [2] Humanized anti-interleukin-6 receptor antibody
    Larry Moreland
    [J]. Current Rheumatology Reports, 2005, 7 (5) : 381 - 381
  • [3] Anti-Interleukin-6 Receptor Antibody Treatment in Inflammatory Autoimmune Diseases
    Ding, Changhai
    Jones, Graeme
    [J]. REVIEWS ON RECENT CLINICAL TRIALS, 2006, 1 (03) : 193 - 200
  • [4] Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases
    Tanaka, Toshio
    Narazaki, Masashi
    Kishimoto, Tadamitsu
    [J]. FEBS LETTERS, 2011, 585 (23) : 3699 - 3709
  • [5] Therapeutic uses of anti-interleukin-6 receptor antibody
    Kang, Sujin
    Tanaka, Toshio
    Kishimoto, Tadamitsu
    [J]. INTERNATIONAL IMMUNOLOGY, 2015, 27 (01) : 21 - 29
  • [6] Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for the treatment of autoimmune disorders
    Tanaka, Toshio
    Hagihara, Keisuke
    Shima, Yoshihito
    Narazaki, Masashi
    Ogata, Atsushi
    Kumanogoh, Atsushi
    [J]. DRUG DEVELOPMENT RESEARCH, 2011, 72 (08) : 717 - 732
  • [7] Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis
    Mihara, Masahiko
    Ohsugi, Yoshiyuki
    Kishimoto, Tadamitsu
    [J]. OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2011, 3 : 19 - 29
  • [8] Implications for White Matter Vulnerability to Anti-interleukin-6 Receptor Antibody Treatment
    Kato, Daisuke
    [J]. INTERNAL MEDICINE, 2020, 59 (22) : 2809 - 2810
  • [9] Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease
    Nishimoto, N
    Kanakura, Y
    Aozasa, K
    Johkoh, T
    Nakamura, M
    Nakano, S
    Nakano, N
    Ikeda, Y
    Sasaki, T
    Nishioka, K
    Hara, M
    Taguchi, H
    Kimura, Y
    Kato, Y
    Asaoku, H
    Kumagai, S
    Kodama, F
    Nakahara, H
    Hagihara, K
    Yoshizaki, K
    Kishimoto, T
    [J]. BLOOD, 2005, 106 (08) : 2627 - 2632
  • [10] Tocilizumab, an anti-interleukin-6 receptor antibody, efficiently ameliorates persistent joint inflammation in rheumatoid arthritis
    Hirabayashi, Yasuhiko
    [J]. MODERN RHEUMATOLOGY, 2021, 31 (01) : 70 - 79